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The interaction between living organisms and the environment requires a balancing act 
between genomic and epigenomic forces. Inflammation and cellular proliferation are 
kept in check by the genes, which code for their components and the microRNAs, which 
are capable of silencing the transcription of these genes. Acetylcholine (ACh) may play 
a unique role in the maintenance of this equilibrium, as the epigenomic inhibition of the 
gene coding for nicotinic receptors, and disinhibits the gene causing anergia in immune 
cells. We hypothesize that age-induced ACh deficiency is the result of an epigenomic 
dysfunction of microRNA-6775 (miR-6775), which silences the transcription of CHRNA7 
gene [coding for alpha 7 nicotinic cholinergic receptors (nAChRs)]. When silenced, this 
gene induces decreased expression of alpha 7 nAChRs, which may predispose elderly 
individuals to inflammation, neuroinflammation, and delirium. We hypothesize further 
that miR-6775-induced hypocholinergia augments the expression of RNF 128, the gene 
related to anergy in lymphocytes (GRAIL). This gene favors regulatory T cells (Tregs), 
promoters of immunologic tolerance, which may predispose to both cancer and sep-
sis-induced immunosuppression.
Keywords: acetylcholine, cell cycle, inflammation, carcinogenesis, immunosuppression
introduction
Altered immunity, low-grade inflammation, and neuroinflammation accompany old age and may 
predispose to infections often progressing to sepsis, sepsis-induced delirium (SID), and cancer. 
Recent studies have shown that aging is associated with a body-wide decrease in nicotine binding to 
nicotinic acetylcholine receptors (nAChRs) (1, 2). Acetylcholine (ACh) depletion is one of the best-
documented hypotheses of delirium, and it is a common knowledge that old age and anticholinergic 
medications predispose to delirium. Recently, it was demonstrated that a preexisting impairment in 
cholinergic signaling was necessary for the pathogenesis of delirium (3).
Non-neuronal ACh is known to participate in cellular proliferation, differentiation, and apoptosis 
throughout the body tissues and organs; however, a direct link between ACh and immune cells’ 
anergia has not been demonstrated. In this article, we hypothesize that age-related hypocholinergia 
predisposes not only to delirium but also to immunosenescence, which is often associated with 
increased risk for cancer and sepsis-induced immunosuppression (SAIS).
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Method
In order to test this hypothesis, we conducted a simple public 
domain search utilizing available on-line microRNA tools, includ-
ing EXIQON miRSearch, DIANA-miRPath v3.0, and Wizemann 
Institute of Science miRBase, and identified miR-6775 (accession 
number MIMAT0027451) as being a regulator of both RNF 128 
and CHRNA7 genes.
Aging, Ach, and Low-Grade inflammation
The immune competent cells of the human body must be aggres-
sive enough to “fire” promptly at intruding pathogens, but tolerant 
enough to avoid autoimmune “friendly fire.” This delicate balance 
between too much and not enough inflammation is facilitated by 
a tight cooperation between the genom and the epigenom. Lack 
of epigenomic supervision, such as microRNA dysfunctions, may 
manifest as impairment in immunity or autoimmunity both of 
which are prevalent in elderly.
Recent studies demonstrate that aging is associated with 
lowered transcription of nAChRs with subsequent low-grade 
inflammation, as failure to properly activate alpha 7 nAChRs 
results in release of pro-inflammatory cytokines (Figure 1). For 
example, postmortem studies of human brains with Alzheimer’s 
disease (AD) reported up to 70% decrease in nAChRs expression 
(2). In addition, it was demonstrated that beta-amyloid itself 
can decrease transcription of nAChRs. With the same token, in 
sepsis, low expression of alpha 7 nAChRs on peripheral blood 
mononuclear cells is associated with uncontrolled inflammation 
and poor prognosis, suggesting age-related predisposition for 
sepsis (4). Furthermore, recent studies show that nicotine pro-
tects against septic injury by activation of alpha 7 nAChRs, which 
probably inhibits tall-like receptors 4 (TLR4) (5).
Studies of prostaglandin pathways, such as cyclooxygenase 
(COX)-1 in microglia and perivascular macrophages, dem-
onstrate that alteration in these pathways may predispose to 
cognitive dysfunction. Subsequently, COX-1 inhibitor SC-560 
provides significant protection against LPS-induced cognitive 
deficits (8). These studies are consistent with the neuroinflam-
matory model of delirium. In addition, preclinical studies 
showed that COX-1 deficient (COX-1−/−) mice show not only 
reduced neuroinflammation and neuronal damage but also 
decreased cellular proliferation after lipopolysaccharide injec-
tion (9). Furthermore, during infection and inflammation, 
COXs enhance generation of prostaglandin E2 (PGE2). PGE2 
is an immune-stimulator as it promotes T-cell activation and 
proliferation. Therefore, a dysfunction of miR-6775, silencing 
the expression of RNF 128 gene may result in excessive immune 
cells activation, including microglia via PGE2. This pathway may 
help explain the beneficial effect of COX-1 inhibitors in cogni-
tive dysfunctions (10).
The RNF 128 gene codes for an enzyme, an ubiquitin ligase, 
which inhibits the transcription of IL-2 and IL-4 cytokine genes. 
Silencing these genes triggers proliferation of Tregs, the anergic 
T cell phenotype (11, 12). Tregs were shown to decrease mitogen-
induced lymphocyte proliferation by directing these cells into 
apoptotic pathways, impairing immune responses (13, 14). 
FiGUre 1 | Activation of alpha 7-cholinergic nicotinic receptors 
(nAchr) on peripheral macrophages decreases cytokine synthesis 
exerting an anti-inflammatory effect (5). A similar cholinergic pathway, 
regulating microglial activation is operational in the CNS (6, 7).
Furthermore, by promoting immune tolerance, Tregs are utilized 
in post-transplant management as they suppress allograft 
rejection (15). On the other hand, the absence of Tregs was 
demonstrated to trigger autoimmunity and inflammation by 
disinhibition of pro-inflammatory T helper cells 17 (Th17) 
(16). These cells access the CNS via diapedesis or through 
the recently described dural lymphatic vessels, spreading 
the inflammation into the brain (17). Interestingly, the pro-
liferation of Th17 is augmented by the absence of alpha 7 
nAChRs, suggesting that silencing CHRNA 7 gene, probably 
by microRNA, induces a Th17 response (16).
MicroRNAs (miRs) are a family of small non-coding 
RNAs, which are physiologically able to silence the expres-
sion of genes, which in return may activate or inhibit next 
tier genes. Therefore, a dysfunctional miR may decrease 
or increase transcription of genes depending on whether it 
silences the activator or the inhibitor of a particular gene. For 
example, aging was demonstrated to increase miR-23b, but 
decrease miR-17, miR-19b, miR-20a, and mir-106a, probably 
by silencing the activator genes (18, 19). Interestingly, miR-
23b was demonstrated to safeguard against autoimmunity and 
to regulate endothelial cells inflammation in sepsis (20, 21).
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Non-Neuronal Ach and the cell cycle
It has been known for more than a decade that peripheral lympho-
cytes derived from patients with AD proliferate less to mitogenic 
stimulation than lymphocytes derived from normal individuals, 
but a connection between the immune cells’ proliferation, apop-
tosis, and ACh signaling has not been established (22, 23). ACh 
is well known for its neurotransmitter role at the synapses and 
the neuromuscular junctions, but its non-neuronal functions have 
only been documented lately (24). Non-neuronal ACh is released 
by different cells into the extracellular space (ECS) of numerous 
tissues, including the brain. Here, it operates in paracrine fashion, 
mainly by modulating cellular cytoskeleton, adapting it for prolif-
eration, differentiation, or apoptosis, depending on the immediate 
cellular need (24). These non-neurotransmitter functions of ACh 
were documented both at phylogenetic and ontogenetic levels (25, 
26). For example, phylogenetically, ACh was present in prokaryotic, 
eukaryotic cells, protozoa, fungi, and plants long before the evolu-
tion of a nervous system; ontogenetically, ACh has been detected 
in human embryos prior to neurogenesis or synaptogenesis (27).
The cholinergic system described on peripheral lymphocytes 
consists of choline acetyltransferase (ChAT), muscarinic and 
nicotinic ACh receptors (mAChRs and nAChRs), and acetylcho-
linesterase (AChE). Aside from inflammation, this system plays 
a major role in lymphocyte proliferation on antigen contact (26, 
27). A non-neuronal cholinergic system was also described in 
the CNS comprised astrocytes, microglia, and endothelial cells 
(27). It was recently demonstrated that astrocytes secrete ChAT 
and that both neuronal and non-neuronal cells express nicotinic 
and muscarinic receptors, suggesting that inflammation and 
cellular proliferation may utilize paracrine ACh signaling (28). 
In the CNS, non-neuronal ACh is synthesized in the ECS from 
choline and acetyl coenzyme A in a reaction catalyzed by the 
astrocyte-secreted ChAT (28). Astrocytic pathology may impair 
ChAT biosynthesis, predisposing to inflammation and aberrant 
cellular proliferation (29). For example, deficient ACh signaling 
may induce post-mitotic neurons to enter the cell cycle, as dem-
onstrated in AD. In this condition, neurons undergo apoptosis as 
they lack the cellular machinery to complete mitosis; they enter 
the cell cycle, progress through the S phase, arrest in the G2 phase, 
and undergo pre-programed cell death (30–32).
Aside from affecting the neurons, aging was demonstrated to 
induce similar changes in astrocytes and microglia. For example, 
preclinical studies demonstrate that aging facilitates upregulation 
of astrocytic aquaporin-4 (AQP-4) proteins with resultant cyto-
toxic edema. Edematous astrocytes may be unable to synthesize 
ChAT, further impairing cholinergic signaling, and predisposing 
to delirium (33, 34). AQP-4 upregulation and astrocytic swelling 
were demonstrated in a variety of age-related diseases, includ-
ing SID, stroke, traumatic brain injury (TBI), brain tumors or 
metastases, brain abscesses, and dehydration (34).
Astrocytic cytotoxic edema with decreased ACh signaling may 
be responsible for the aberrant neuronal re-entry into the cell 
cycle (34). Interestingly, another microRNA, miR-6739 (accession 
number MIMAT0027379), controls three genes: the cell division 
and apoptosis regulator 1 (CCAR1, ENSG 00000060339), regulator 
of cell cycle (RGCC, ENSG00000102760), and Meteorin glial cell 
differentiation regulator (METRN, ENSG 00000103260). These 
genes may link age-related changes in immunity with astrocyte 
pathology and neuronal re-entry into the cell cycle. Moreover, miR-
6775 and miR-6739 may regulate central and peripheral immunity 
(astrocytes are part of the innate immune system) and keep neuronal 
cell cycle in check, assuring stability of these cells in G0 phase.
Microglia are also components of the innate immune system, 
and impairments in cholinergic signaling were described in aging 
microglia. Interestingly, preclinical studies show that selective 
removal of senescent microglia from the brain of older animals 
can delay or prevent neurodegeneration (35). In addition, micro-
glia-mediated neuroinflammation via TLR4 was hypothesized 
in the pathogenesis of post-operative delirium (36). Studies in 
rodents demonstrate that CHRNA 7 gene-induced expression of 
alpha 7 nAChRs suppresses microglial inflammation and shifts 
these cells toward restorative phenotypes (37, 38). Therefore, 
miR-6775-induced silencing of CHRNA 7 gene favors microglial 
pro-inflammatory phenotype.
Other post-mitotic cells, such as cardiomyocytes, are known 
for their ability to re-enter the cell cycle and to synthesize ACh (39, 
40). Recent studies demonstrate that ACh deficiency may induce 
apoptosis in cardiomyocytes, while vagal electrical stimulation in 
rodents was found to protect against it (41). In addition, the role 
of ACh in inducing cell cycle entry is relevant for carcinogenesis. 
For example, mAChRs activation in small cell lung carcinoma 
induces cancer cells to arrest in S and G2/M phases with a con-
comitant decrease in DNA synthesis (42). In human glioblastoma 
cells, ACh inhibits malignant cells’ entry into the cell cycle via 
M2 receptor activation (43). Recently, it was demonstrated that 
cholinesterase enzymes decrease malignant cells’ proliferation in 
hepatocellular carcinoma (44). In other cancers, ACh seems to 
promote malignant growth, probably depending on the subtype 
of muscarinic receptors activated. For example, in colon cancer, 
upregulation of M3 muscarinic receptors is associated with 
increased malignant cells’ proliferation (45).
Taken together these data suggest that ACh binding to 
mAChRs, expressed by lymphocytes, triggers their proliferation 
in response to mitogens. Conversely, lack of such binding, caused 
by deficient ACh, may result in immune anergia (12). On the other 
hand, in post-mitotic neurons, binding of ACh to mAChRs (or 
receptor subtypes) may keep the cell cycle in check by preventing 
exit from G0 phase. Deficient ACh binding may induce cell cycle 
instability with aberrant attempts to initiate mitosis (46).
conclusion
The human immune system is hard-wired with the CNS by auto-
nomic fibers and by the newly described dural lymphatic vessels. 
Low grade inflammation and neurosenescence were described in 
the elderly both in the immune system and the CNS, predispos-
ing to aging pathology, such as infections, sepsis, and delirium. 
Dysfunctional miRs may be responsible for the age-related 
impairment in cholinergic signaling, inducing both inflamma-
tion and neuronal apoptosis after aberrant attempts to initiate the 
cell cycle. miR-6775 and miR-6739 may modulate inflammation, 
cell cycle, apoptosis, and glial functions, and may qualify for the 
name of “deliromiRs.”
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